Skip to main content
SpringerLink
Log in

Serum (Circulating) Tumor Markers for Breast Cancer

  • Conference paper
Adjuvant Therapy of Breast Cancer V

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 140))

Abstract

Tumor markers are defined as substances or processes that can be assayed in order to predict risk, presence, and/or current or future behavior of malignancy (Hayes 1994). These substances or processes differ from the nonmalignant state as a result of the malignant process. A variety of specimen types might be assayed for tumor markers for breast cancer (Table 1). In this regard, germ-line genetic markers in all cells of the body might predict a relative susceptibility to the development of breast cancer. Markers of early malignant transformation might be assayed within breast tissue itself, either through biopsy or needle aspirate of epithelial tissue or by aspiration of nipple ductule contents. In patients who have established malignancy, markers can be monitored in breast cancer tissue in order to develop categories of presumed biological behavior or in distant, non-breast tissue to detect the presence of metastatic disease. However, soluble, circulating tumor-associated markers that can be detected in plasma and/or serum might reflect a more immediate status of both tumor burden and biology.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Cardoso de Almeida PC, Pestana CB (1992) Immunohistochemical markers in the identification of metastatic breast cancer. Breast Cancer Res Treat 21: 201–210

    Google Scholar 

  • Carney W, Hamer P, Petit D, Retos C, Greene R, Zabrecky J, McKenzie S, Hayes DF, Kufe DW, DeLellis R, Naber S, Wolfe H (1991) Detection and quantitation of the neu oncoprotein. J Tumor Marker Oncol 6: 53–72

    Google Scholar 

  • Colomer R, Ruibal A, Genolla J, Rubio D, Del Campo JM, Bodi R, Salvador L (1989a) Circulating CA 15–3 levels in the postsurgical follow-up of breast cancer patients and in non-malignant diseases. Breast Cancer Res Treat 13: 123–133

    Article  PubMed  CAS  Google Scholar 

  • Colomer R, Ruibal A, Salvador L (1989b) Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic disease. Cancer 64: 1674–81

    Article  PubMed  CAS  Google Scholar 

  • Davidoff A, Iglehart JD, Marks J (1992) Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. Proc Natl Acad Sci USA 89: 3439–3442

    Article  PubMed  CAS  Google Scholar 

  • Disis ML, Calenoff E, McLaughlin G, Murphy AE, Chen W, Groner B, Jeschke M, Lydon N, McGlynn E, Livingston RB, Moe R, Cheever MA (1994) Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res 54: 16–20

    PubMed  CAS  Google Scholar 

  • Donegan WL (1992) Evaluation of a palpable breast mass. N Engl J Med 327: 937–942

    Article  PubMed  CAS  Google Scholar 

  • Early Breast Cancer Trialists’ Collaborative Group T (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31000 recurrences and 24 000 deaths among 75 000 women. Lancet 339:1–15, 71–85

    Google Scholar 

  • Eddy DM (1989) Screening for breast cancer. Ann Intern Med 111:389–399

    PubMed  CAS  Google Scholar 

  • Elledge RM, McGuire WL, Osborne CK (1992) Prognostic factors in breast cancer. Semin Oncol 19: 244–253

    PubMed  CAS  Google Scholar 

  • Futreal PA, Liu Q, Shattuck-Eidens D, Cochran C, Harshaman K, Tavtigian S, Bennett LM, Haugen-Strano A, Swensen J, Miki Y, Eddington K, McClure M, Frye C, Weaver-Feldhaus J, Ding W, Gholami Z, Söderqvist P, Terry L, Jhanwar S, Berchuck A, Iglehart JD, Marks J, Ballinger DG, Barrett JC, Skolnick MH, Kamb A, Wiseman R (1994) BRCA1 mutations in primary breast and ovarian carcinomas. Science 266: 120–122

    Article  PubMed  CAS  Google Scholar 

  • GIVIO Investigators (1994) Impact of follow-up and testing on survival and health-related quality of life in breast cancer patients: a multicenter randomized controlled trial. J Am Med Assoc 271: 1587–1592

    Article  Google Scholar 

  • Harris JR, Lippman ME, Veronesi U, Willett W (1992) Breast cancer (first of three parts). N Engl J Med 327: 319–328

    Article  PubMed  CAS  Google Scholar 

  • Hayes DF (1993) Tumor markers for breast cancer. Ann Oncol 4: 807–819

    PubMed  CAS  Google Scholar 

  • Hayes DF (1994) Hematology/Oncology Clinics of North America:,tumor markers in adult solid malignancies. Saunders, Philadelphia

    Google Scholar 

  • Hayes DF, Kaplan W (1991) Evaluation of patients following primary therapy. In: Harris J, Hellman S, Henderson I, Kinne D (eds) Breast diseases. Lippincott, Philadelphia, pp 505–525

    Google Scholar 

  • Hayes DF, Zurawski VR Jr, Kufe DW (1986) Comparison of circulating CA15–3 and carcinoembryonic antigen levels in patients with breast cancer. J Clin Oncol 4: 1542–1550

    PubMed  CAS  Google Scholar 

  • Hayes DF, Kiang DT, Korzun A, Tondini C, Wood W, Kufe D (1988) CA15–3 and CEA spikes during chemotherapy for metastatic breast cancer. Proc Am Soc Clin Oncol 7: 38a

    Google Scholar 

  • Hayes DF, Tondini C, Kufe DW (1992) Clinical applications of CA15–3. In: Sell S (ed) Serological cancer markers. Humana, Totowa, pp 281–307

    Chapter  Google Scholar 

  • Hayes DF, Cirrincione C, Carney W, Rodrigue S, Berry D, Younger J, Panasci L, Millard F, Duggan D, Henderson IC, Kufe DW (1993) Elevated circulating HER2/neu related protein ( NRP) is associated with poor survival in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 12: 58

    Google Scholar 

  • Hayes DF, Henderson IC, Shapiro CL (1995) Treatment of metastatic breast cancer: present and future prospects. Semin Oncol 22 (suppl 5): 5–21

    PubMed  CAS  Google Scholar 

  • Hoskins KF, Stopfer JE, Calzone KA, Merajver SD, Rebbeck TR, Garber JE, Weber BL (1995) Assessment and counseling for woment with a family history of breast cancer: a guide for clinicians. J Am Med Assoc 273: 577–585

    Article  CAS  Google Scholar 

  • Hull DF III, Clark GM, Osborne CK, Chamness GC, Knight WA III, McGuire WL (1983) Multiple estrogen receptor assays in human breast cancer. Cancer Res 43: 413–416

    PubMed  Google Scholar 

  • Kallioniemi O, Oksa H, Aaran R, Hietanen T, Lehtinen M, Koivula T (1988) Serum CA15–3 assay in the diagnosis and follow-up of breast cancer. Br J Cancer 58: 213–215

    Article  PubMed  CAS  Google Scholar 

  • Kaluzny AD, Rimer B, Harris R (1994) The National Cancer Institute and guideline development: lessons from the breast cancer screening controversy. J Natl Cancer Inst 86: 901–903

    Article  PubMed  CAS  Google Scholar 

  • Kelsey J, Berkowitz G (1988) Breast cancer epidemiology. Cancer Res 48: 5615–5623

    PubMed  CAS  Google Scholar 

  • Leitzel K, Teramoto Y, Sampson E, Mauceri J, Langton 13C, Demers L, Podczaski E, Harvey H, Shambaugh S, Volas G, Weaver S, Lipton A (1992) Elevated soluble cerbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients. J Clin Oncol 10: 1436–1443

    CAS  Google Scholar 

  • Leitzel K, Teramoto Y, Konrad K, Chinchilli VM, Volas G, Grossberg H, Harvey H, Demers L, Lipton A (1995) Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 13: 1129–1135

    PubMed  CAS  Google Scholar 

  • Maigre M, Fumoleau P, Ricolleau G, Guillard Y, Cussac A, Vignoud J, Ahkong V (1988) CA15–3 in breast cancer. Comparison with CEA ( French ). Semin Hop Paris 64: 9–13

    Google Scholar 

  • Mazoujian G, Pinkus GS, Davis S, Haagensen DE Jr (1983) Immunohistochemistry of a gross cystic disease fluid protein (GCDFP-15) of the breast: a marker of apocrine epithelium and breast carcinomas with apocrine features. Am J Pathol 110: 105–112

    PubMed  CAS  Google Scholar 

  • McGuire WL, Tandon AK, Allred DC, Chamness GC, Ravdin PM, Clark GM (1992) Treatment decisions in axillary node-negative breast cancer patients. J Natl Cancer Inst Monogr 11: 173–180

    PubMed  Google Scholar 

  • Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W (1994) A strong candidate for the breast and ovarian cancer suceptibility gene BRCA1. Science 266: 66–71

    Article  PubMed  CAS  Google Scholar 

  • National Advisory Council for Human Genome Research (1994) Statement on use of DNA testing for presymptomatic identification of cancer risk. J Am Med Assoc 271: 785

    Article  Google Scholar 

  • Nguyen M, Watanabe H, Budson A, Richie JP, Hayes DF, Folkman J (1992) Basic fibroblast growth factor (bFGF) is elevated in the urine of patients with a wide variety of neoplasms. Mol Biol Cell 3: 234A

    Google Scholar 

  • Nyström L, Rutqvist LE, Wall S, Lindgren A, Lindqvist M, Rydén S, Andersson I, Bjurstam N, Fagerberg G, Frisell J, Tabâr L, Larsson L-G (1993) Breast cancer screening with mammography: overview of Swedish randomised trials. Lancet 341: 973–978

    Article  PubMed  Google Scholar 

  • Osborne CK (1991) Receptors. In: Harris J, Hellman S, Henderson I, Kinne D (eds) Breast diseases. Lippincott, Philadelphia, pp 301–325

    Google Scholar 

  • Perey L, Hayes D, Tondini C, van Melle G, Bauer J, Lemarchand T, Reymond M, Mach J, Leyvraz S (1990) Elevated CAl25 levels in patients with metastatic breast carcinoma. Br J Cancer 62: 668–670

    Article  PubMed  CAS  Google Scholar 

  • Raemaekers JM, Beex LV, Koenders AJ, Pieters GF, Smals AG, Benraad TJ, Kloppenborg PW (1984) Concordance and discordance of estrogen and progesterone receptor content in sequential biopsies of patients with advanced breast cancer: relation to survival. Eur J Cancer Clin Oncol 20: 1011–1018

    Article  PubMed  CAS  Google Scholar 

  • Rosen P, Groshen W, Saigo P, Kinne D, Hellman S (1989) A long-term follow-up study of survival in Stage I (T1NOMO) and Stage II (T1N1MO) breast carcinoma. J Clin Oncol 7: 355–366

    PubMed  CAS  Google Scholar 

  • Rosselli Del Turco M, Palli D, Cariddi A, Ciatto S, Pacini P, Distante V (1994) Intensive diagnostic follow-up after treatment of primary breast cancer: a randomized trial. J Am Med Assoc 271: 1593–1597

    Article  Google Scholar 

  • Ruibal A, Colomer R, Genolla J (1987) Prognostic value of CA15–3 serum levels in patients having breast cancer. Horm Metab 1: 11–15

    Google Scholar 

  • Sacks NP; Stacker SA, Thompson CH, Collins JP, Russell IS, Sullivan JA, McKenzie IF (1987) Comparison of mammary serum antigen (MSA) and CA15–3 levels in the serum of patients with breast cancer. Br J Cancer 56: 820–824

    Article  PubMed  CAS  Google Scholar 

  • Safi F, Kohler I, Rottinger E, Suhr P, Beger HG (1989) Comparison of CA15–3 and CEA in diagnosis and monitoring of breast cancer. Int J Biol Markers 4: 207–214

    PubMed  CAS  Google Scholar 

  • Sekine H, Hayes DF, Ohno T, Keefe KA, Schaetzl E, Bast RC, Knapp R, Kufe DW (1985) Circulating DF3 and CAl25 antigen levels in serum from patients with epithelial ovarian carcinoma. J Clin Oncol 3: 1355–1363

    PubMed  CAS  Google Scholar 

  • Shattuck-Eidens D, McClure M, Simard J, Labire F, Narod S, Couch F, Hoskins K, Weber B, Castilla L, Erdos M, Brody L, Friedman L, Ostermeyer E, Szabo C, King M-C, Jhanwar S, Offit K, Norton L, Gilewski T, Lubin M, Osborne M, Black D, Boyd M, Steel M, Ingles S, Haile R, Lindblom A, Olsson H, Borg A, Bishop DT, Solomon E, Radice P, Spatti G, Gayther S, Ponder B, Warren W, Stratton M, Liu Q, Fujimura F, Lewis CMHS, Goldgar DE (1995) A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene: implications for presymptomatic testing and screening. J Am Med Assoc 273: 535–541

    Article  CAS  Google Scholar 

  • Smart YC, Rogers KM, Brien JH, Stewart JF, Burton RC (1989) Factors affecting MSA levels in normal women and women with breast cancer. Aust NZ J Surg 59:805–8–9

    Google Scholar 

  • Stierer M, Rosen HR (1989) Influence of early diagnosis on prognosis of recurrent breast cancer. Cancer 64: 1128–1131

    Article  PubMed  CAS  Google Scholar 

  • Tondini C, Hayes DF, Gelman R, Henderson IC, Kufe DW (1988) Comparison of CA15–3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer. Cancer Res 48: 4107–4112

    PubMed  CAS  Google Scholar 

  • Tondini C, Hayes DF, Kufe D (1989) Circulating tumor markers in breast cancer. In: Henderson IC (ed) Diagnosis and therapy of breast cancer. Saunders, Philadelphia, pp 653–674

    Google Scholar 

  • Watanabe H, Nguyen M, Schizer M, Li V, Hayes DF, Sallan S, Folkman J (1992) Basic fibroblast growth factor in human serum: a prognostic test for breast cancer. Mol Biol Cell 3: 324A

    Google Scholar 

  • Wright C, Nicholson S, Angus B, Sainsbury JRC, Farndon J, Cairns J, Harris AL, Home CHW (1992) Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 65: 118–121

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Breast Evaluation Center, Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney St., Boston, MA, 02115, USA

    D. F. Hayes

Authors
  1. D. F. Hayes
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Medicine C, Kantonsspital, CH-9007, St. Gallen, Switzerland

    Hans Jörg Senn  & Beat Thürlimann  & 

  2. Division of Biostatistics, Dana Farber Cancer Institute, 44, Binney Street, 02115, Boston, MA, USA

    Richard D. Gelber Ph.D.

  3. Ospedale Civico, CH-6900, Lugano, Switzerland

    Aron Goldhirsch

Rights and permissions

Reprints and permissions

Copyright information

© 1996 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Hayes, D.F. (1996). Serum (Circulating) Tumor Markers for Breast Cancer. In: Senn, H.J., Gelber, R.D., Goldhirsch, A., Thürlimann, B. (eds) Adjuvant Therapy of Breast Cancer V. Recent Results in Cancer Research, vol 140. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-79278-6_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-79278-6_12

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-79280-9

  • Online ISBN: 978-3-642-79278-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation